BPC-157 Half Life

What is the half life of BPC-157?

There is no reliable, peer-reviewed human half-life value published for BPC-157. The accurate answer is that any confident human number is not backed by a completed human pharmacokinetic trial. Where measured data do exist, they come from animals: after single intravenous administration, single intramuscular administrations at three increasing doses, and repeated intramuscular administration, the elimination half-life of prototype BPC157 was less than 30 minutes, and BPC157 showed linear pharmacokinetic behavior in rats and beagle dogs (He et al., 2022).

"Half-life" means the time it takes for the blood concentration of a compound to fall by half. Establishing it requires dosing a defined amount, drawing blood at set time points, measuring concentration with a validated assay, and fitting the decay curve. That full sequence has been completed in animals but not in humans. So when you read a confident "the human half-life is X hours" claim, the correct posture is skepticism until a real human citation is attached.

Why is the human pharmacokinetic data so thin?

Because most published BPC-157 work is preclinical and was not designed to measure human plasma half-life. A 2020 review reappraised BPC 157 across gastric cytoprotection and organoprotection, describing its protection of stomach cells, its presence in gastric mucosa and gastric juice, and protection of other tissues such as skin, liver, pancreas, heart, and brain (Sikiric et al., 2020, PMC7096228). That body of work centers on tissue outcomes rather than human concentration-versus-time modeling.

Several factors compound the gap:

• BPC-157 has not completed the regulated human clinical trial pathway that normally produces published human PK profiles.
• Peptide assays in blood are technically demanding, and short peptides can be hard to detect and quantify reliably.
• Much of the circulating information repeats figures that either lack a primary source or misapply the animal half-life to humans.

The result is that animal data can suggest general behavior, but extrapolating a precise human half-life from rodent and canine studies is not the same as measuring it in people.

What can we reasonably infer from BPC-157 pharmacokinetics in animals?

We can infer that clearance is rapid, because that is what the animal data show, but inference about the human value is still not measurement. In the primary animal PK study, the mean absolute bioavailability of BPC157 after intramuscular injection was approximately 14 to 19 percent in rats and 45 to 51 percent in beagle dogs (He et al., 2022). The same work traced how the peptide is broken down and removed: using tritium-labeled BPC157 and radioactivity examination, the main excretory pathways were shown to involve urine and bile (He et al., 2022), and six metabolites were identified by high-performance liquid chromatography-tandem mass spectrometry in rat plasma, bile, urine, and feces after a single intramuscular administration (He et al., 2022).

This distinction matters. "Short based on measured animal clearance" is a defensible inference for what a human value might look like. It is not a substitute for a human half-life, which is a number that only a human trial can produce.

Known versus unknown: BPC-157 pharmacokinetics at a glance

The table below separates what the literature supports from what remains open. Note the split between characterized animal data and the missing human rows.

If a source fills the human rows with a hard number, ask for the primary human citation. If it cannot produce one, the figure is unverified or is an animal value applied to people.

How does the BPC-157 half life evidence compare to peptides with published human PK?

On the primary question of a human half-life, BPC-157 sits behind peptides that have completed human trials with published pharmacokinetics. For contrast, growth hormone secretagogues and GLP-1 class agents have peer-reviewed human data: CJC-1295 was shown to sustain GH and IGF-1 in humans over days (Teichman et al., 2006), tesamorelin has published human trial outcomes including about a 15 percent reduction in visceral adipose tissue (Falutz et al., 2007), and semaglutide has large registered human trials (Wilding et al., 2021).

The point is not that these are comparable compounds. The point is that a real human PK evidence base looks like named human trials with measured values. BPC-157 has measured animal PK but not a measured human half-life, and this page will not pretend otherwise.

Should you rely on the half-life numbers posted on forums?

No. Human half-life numbers circulated on forums and vendor pages generally do not trace to a completed human PK study, and some simply reuse the animal figure as if it were human. The measured animal value is real and under 30 minutes (He et al., 2022), but a human half-life is not the same measurement. A citation to a real primary human trial is the minimum bar for a human claim. Any decision about personal use should go through a qualified clinician who can weigh the actual evidence and its limits.